Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume – Should You Buy?

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) shares saw unusually-high trading volume on Monday . Approximately 39,413 shares were traded during trading, an increase of 36% from the previous session’s volume of 29,002 shares.The stock last traded at $15.17 and had previously closed at $14.51.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. HC Wainwright set a $37.00 price target on Pharming Group and gave the stock a “buy” rating in a report on Thursday, March 12th. Weiss Ratings cut shares of Pharming Group from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday. Oppenheimer reaffirmed an “outperform” rating and set a $41.00 target price (down from $42.00) on shares of Pharming Group in a research note on Friday, March 13th. Wall Street Zen upgraded shares of Pharming Group to a “strong-buy” rating in a research report on Saturday, December 27th. Finally, Zacks Research downgraded shares of Pharming Group from a “hold” rating to a “strong sell” rating in a research note on Thursday, March 12th. Two analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Pharming Group has an average rating of “Hold” and a consensus price target of $39.00.

Pharming Group Trading Up 0.4%

The company has a 50 day moving average of $17.15 and a 200-day moving average of $16.10. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.03 and a current ratio of 2.59. The stock has a market cap of $1.09 billion, a price-to-earnings ratio of 1,549.00 and a beta of 0.04.

Pharming Group (NASDAQ:PHAR) last released its earnings results on Thursday, March 12th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.08). The firm had revenue of $106.50 million during the quarter, compared to analyst estimates of $111.76 million. Pharming Group had a net margin of 0.71% and a return on equity of 1.08%. On average, research analysts anticipate that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current year.

Institutional Investors Weigh In On Pharming Group

Several large investors have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC acquired a new stake in Pharming Group during the 2nd quarter worth approximately $32,000. SmartHarvest Portfolios LLC acquired a new stake in shares of Pharming Group in the fourth quarter valued at $224,000. Millennium Management LLC purchased a new position in Pharming Group in the fourth quarter valued at $360,000. Finally, NewEdge Advisors LLC grew its stake in Pharming Group by 11,310.3% during the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock worth $510,000 after purchasing an additional 28,615 shares in the last quarter. 0.03% of the stock is owned by hedge funds and other institutional investors.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.